Filing Details
- Accession Number:
- 0001438133-21-000226
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-12-01 19:59:13
- Reporting Period:
- 2021-11-29
- Accepted Time:
- 2021-12-01 19:59:13
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1438133 | Tandem Diabetes Care Inc | TNDM | Surgical & Medical Instruments & Apparatus (3841) | 204327508 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1866570 | James Leal | C/O Tandem Diabetes Care, Inc. 11075 Roselle Street San Diego CA 92121 | Svp, Operations | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-11-29 | 310 | $0.00 | 4,162 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-11-29 | 154 | $129.66 | 4,008 | No | 4 | F | Direct | |
Common Stock | Acquisiton | 2021-11-29 | 1,667 | $51.50 | 5,675 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2021-11-29 | 238 | $82.34 | 5,913 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-11-29 | 1,236 | $130.64 | 4,677 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-11-29 | 664 | $131.54 | 4,013 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-11-29 | 5 | $132.92 | 4,008 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | F | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted Stock Unit | Acquisiton | 2021-11-29 | 310 | $0.00 | 310 | $0.00 |
Common Stock | Stock Option | Acquisiton | 2021-11-29 | 1,667 | $51.50 | 1,667 | $51.50 |
Common Stock | Stock Option | Acquisiton | 2021-11-29 | 238 | $82.34 | 238 | $82.34 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
3,097 | No | 4 | M | Direct | ||
25,000 | No | 4 | M | Direct | ||
7,148 | No | 4 | M | Direct |
Footnotes
- Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
- Represents shares of common stock received upon exercise of a stock option award.
- The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2020.
- The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $130.19 to $131.00. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
- The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $131.48 to $132.24.The Reporting Person undertakes to provide the SEC, the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
- Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan (the 2013 Plan).
- Each RSU represents a contingent right to receive one share of common stock of the Company.
- RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/27/2021, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.
- The options vested as to twenty-five (25%) of the underlying shares on 2/15/2020, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the terms of the 2013 Plan.
- The expiration date for these options is 10 years from the date of grant.
- The options vested as to twenty-five (25%) of the underlying shares on 5/27/2021, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the 2013 Plan.